SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Biogen’s Diranersen Slowed Clinical Decline by 38% at Two Years

The reported result used the CDR-SB measure and a 60 mg twice-yearly regimen.

BIIB

Related stories